The use of cardiac biomarkers in veterinary medicine: the equine perspective

Diergeneeskundig gebruik van cardiogene biomarkers: focus op het gebruik bij paarden

N. Van Der Vekens, A. Decloedt, D. De Clercq, T. Verheyen, G. van Loon

Department of Large Animal Internal Medicine
Faculty of Veterinary Medicine, Ghent University
Salisburylaan 133, 9820 Merelbeke, Belgium
Nicky.VanDerVekens@Ugent.be

ABSTRACT
In human medicine, cardiac biomarkers, such as natriuretic peptides and troponins, are routinely used for the diagnosis, prognosis and monitoring of heart diseases. Similarly, these biomarkers are determined in small animals to differentiate non-cardiac from cardiac diseases. Knowledge about these biomarkers in horses is limited and requires further investigation. The first equine studies about atrial natriuretic peptide (ANP) and N-terminal ANP (NT-proANP) are promising, and show a clear correlation with atrial dimension size. Equine brain natriuretic peptides assays are still unavailable. The troponins, in particular troponin I, have been more extensively studied in horses, and their use for the diagnosis of myocardial damage has been fully demonstrated. They have replaced the less specific lactate dehydrogenase and creatine kinase isoenzymes, which makes the use of the last mentioned no longer legitimate. A final possible equine biomarker is aldosterone. Reference values in horses have been established. However, in only one study, a correlation between aldosterone and cardiac disease has been reported.

SAMENVATTING
Cardiale biomarkers, zoals natriuretische peptiden en troponinen, worden reeds routinematig in de humane geneeskunde gebruikt voor de diagnose, prognose en monitoring van hartaandoeningen. Hoewel ze ook in de kleine huisdierensector regelmatig bepaald worden om cardiologische en niet-cardiologische aandoeningen van elkaar te onderscheiden, is de literatuur omtrent het gebruik bij paarden beperkt. Bij paarden werd reeds een significante correlatie aangetoond tussen het ‘atrial natriuretic peptide’ (ANP), N-terminal ANP (NT-proANP) en de voorkamergrootte. Specifieke equine testen voor ‘brain natriuretic peptide’ (BNP) of ‘N-terminal BNP’ (NT-proBNP) bepaling ontbreken echter nog steeds. Troponinen (vooral troponine I) zijn meer uitgebreid bestudeerd bij het paard. Ze worden reeds gebruikt voor de diagnose van myocardschade en vervangen de minder specifieke lactaatdehydrogenase en creatinekinase iso-enzymen, waardoor het gebruik van deze laatste niet meer gerechtvaardigd is. Een laatste mogelijk belangrijke biomarker is aldosteron, maar aangezien slechts één studie bij paarden een correlatie aangetoond heeft tussen de aldosteronconcentratie en hartaandoeningen is uitgebreider onderzoek nodig.

INTRODUCTION
Over the last two decades, different hormones, enzymes and other proteins have appeared as markers for cardiac problems. In human medicine, one of the most important applications of these cardiac biomarkers is to diagnose acute myocardial infarction in patients with chest pain (Christenson et al., 1998). A number of these proteins also play an important role in assessing prognosis in cardiac patients, and the combination of these individual biomarkers will probably be used in the future as guidance for therapy; the so-called multi-marker strategies (Böhm et al., 2011).

Similar to human medicine, a correlation between the cardiac biomarkers and the prognosis of cardiac disease has been found in animals (Greco et al., 2003). The recent literature describes the utility of these peptides for distinguishing cardiac from non-cardiac diseases in small animals (Fox et al., 2009). These markers have also found their way in equine cardiology for assessing the severity of heart valve diseases (Trachsel et al., 2011). This article reviews the most important cardiac biomarkers and their use in veterinary, and more particularly, equine medicine. Although there are many unresolved questions about the different biomarkers, their future use to screen cardiac diseases is realistic.
Table 1 summarizes the main cardiac biomarkers used in human medicine. The troponins and natriuretic peptides are mostly utilized in daily practice, but also aldosterone, a hormone of the renin – angiotensin-al-dosterone system (RAAS) can be measured to evaluate the cardiac state.

THE NATRIURETIC PEPTIDES, MARKERS OF MYOCYTE STRESS

Physiology and structure

In mammals, there are three main natriuretic peptides: the atrial natriuretic peptides (ANP), the brain natriuretic peptides (BNP) and the C-type natriuretic peptide (CNP). Their main goal is fluid homeostasis. They are released in case of increased intravascular volume and thus atrial or ventricular stretch in an attempt to decrease cardiac overload by diuresis, natriuresis and vasodilatation. Since CNP only causes mild diuresis and natriuresis, only atrial and brain natriuretic peptides are used in clinical practice to detect cardiac disease (Goetze et al., 2003; Takei et al., 2011).

The atrial natriuretic peptides are mostly stored as pro-hormones (proANP1-126) in numerous granules in the atrial cardiomyocytes. However, they are also present in other organs, such as the pituitary, lungs, hypothalamus and kidneys (Kokkonen et al., 2002; Hayek and Nemer, 2010). In response to atrial stretch, the pro-ANP1-126 molecule is split into an inactive NH2-terminal peptide (NT-proANP1-98) and a biologically active (COOH-terminal) ANP99-126 molecule, which are both released into the bloodstream (Figure 1). After release, ANP has a short half-life of about 2-5 minutes in humans. Since the half-life of NT-proANP is longer (55-60 minutes), NT-proANP can be used to assess endogenous secretion of ANP (Thibault et al., 1987; Ruskoaho, 1992; Kokkonen et al., 2002). The structure of the ANP-molecules is well conserved, and 100% homology exists between the equine and human ANP (Table 2), which implies that human tests can be used to measure the ANP concentration in equine blood (Richter et al., 1998). NT-proANP is more species-specific with only 80-90% homology between the equine and the human NT-proANP peptide (Kokkonen, 2002).

Brain natriuretic peptide was first discovered in the porcine brain. It is currently often called the B-type natriuretic peptide because its main production site is ac-
In contrast to atrial natriuretic peptides, BNP is more related to ventricular pathological changes. In healthy individuals, BNP gene expression occurs mainly in the atria. However, an up-regulation in the ventricles can be found in people with heart failure (Goetze, 2004a; Hall, 2005). Similar to the atrial natriuretic peptides, activation of proBNP_1-108 results in cleavage of this molecule into a biologically inactive (NT-proBNP_1-76) and an active component (BNP_77-108) (Hall, 2005). Both BNP (12.1 min) and NT-proBNP (120 min) have a longer half-life than the atrial natriuretic peptides, which makes them better targets for diagnostic blood testing (Kemperman et al., 2004; Kimmura et al., 2007).

In comparison with ANP, the B-type peptides are genetically very variable between species (Takei et al., 2011) (Table 2). Therefore, a human test cannot be used in veterinary practice. A specific test is available for small animals (Cardiopet proBNP, IDEXX Vet Med Lab, Hoofddorp, the Netherlands). However, an equine test is not available yet. Since there is a gross similarity (±90% homology) between the equine and the porcine BNP peptides, a porcine test could potentially be used to measure the BNP concentration in equine blood (Table 2). The homology between these molecules was first suggested in 1995, when antibodies against porcine BNP were utilized for the detection of BNP-like molecules in the equine atria (Mifune et al., 1995).

Table 2. Comparison of human, equine, porcine, canine and feline amino-acids sequences of atrial and brain natriuretic peptides. In contrast to ANP, BNP is very variable between species. The equine B-type natriuretic peptide has a greater resemblance to the porcine form than the human BNP-molecule. The red-colored amino-acids are species specific (adapted from Richter et al., 1998; Goetze, 2004; Takei et al., 2011).

<table>
<thead>
<tr>
<th>Atrial natriuretic peptide</th>
<th>Atrial natriuretic peptide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y</td>
</tr>
<tr>
<td>Equine</td>
<td>S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y</td>
</tr>
<tr>
<td>Porcine</td>
<td>S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y</td>
</tr>
<tr>
<td>Canine</td>
<td>S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y</td>
</tr>
<tr>
<td>Feline</td>
<td>S L R R S S C F G G R M D R I G A Q S G L G C N S F R Y</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brain natriuretic peptide</th>
<th>Brain natriuretic peptide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equine</td>
<td>S P K M M R N S G C F G R R L D R I G S F S G L G C N V L R R Y</td>
</tr>
<tr>
<td>Porcine</td>
<td>S P K T M R D S G C F G R R L D R I G S L S G L G C N V L R R Y</td>
</tr>
<tr>
<td>Canine</td>
<td>S P K M M H K S G C F G R R L D R I G S L S G L G C N V L R Y K</td>
</tr>
<tr>
<td>Feline</td>
<td>S S K M M R D S R C F G R R L D R I G S L S G L G C N V L R R H</td>
</tr>
</tbody>
</table>
The use of natriuretic peptides in human and small animal veterinary medicine

In human medicine, the brain natriuretic peptides are frequently used for the diagnosis, prognosis and therapy monitoring in patients with heart failure. Even though the atrial natriuretic peptides were discovered first, nowadays, the B-types are used more often in clinical practice, because of their longer half-life (Woodard and Rosado, 2007). Not only are levels of BNP and NT-proBNP elevated in cases of heart failure, also non-cardiac pathologies, such as acute pulmonary embolism, pulmonary hypertension, sepsis or hyperthyroidism may influence their concentration (Felker et al., 2006).

Adjusted BNP and NT-proBNP levels are used in emergency departments to differentiate between non-cardiac and cardiac causes of dyspnea (Maisel et al., 2002; Rogers et al., 2009). Similarly, a species-specific NT-proBNP test allowed to distinguish acute respiratory problems caused by heart failure from non-cardiac causes in small animals (Fox et al., 2009; Ettinger et al., 2012). In human medicine, the brain natriuretic peptides are also used for the detection of myocardial ischemia in patients with acute coronary syndrome. Compared with the conventional markers (e.g. troponin I), the NT-proBNP molecules rise much higher in an earlier phase, making them more suitable for early diagnosis (Tsai et al., 2010). Myocardial ischemia is rare in small animals, but in resemblance to humans a significant increase in NT-proBNP concentration has been found in a canine model of myocardial ischemia (Hori et al., 2012). A much more common disease in small animals, especially in cats, is hypertrophic cardiomyopathy (HCM). Investigation into the use of NT-proBNP elevation as screening factor for this disease revealed that it can only be used for the detection of cats with severe HCM: the NT-proBNP concentration in cats with moderate or mild HCM is not significantly different from normal individuals (Hsu et al., 2009).

As mentioned above, the use of atrial natriuretic peptides in human clinical practice is limited (Saito, 2010). Recently, the diagnostic value of a fragment of the proANP molecule (mid-region proANP) for heart failure has been recognized (Ghosh and Haddad, 2011), and a multi-marker strategy is emerging. Because of the species-similarity of the ANP-molecules, no specific veterinary test had to be developed and a human radio-immunoassay (RIA) has been validated in dogs as predicting factor for survival (Greco et al., 2003). An ANP cut-off value of 25 pg/mL shows a high specificity and sensitivity for identifying dogs with heart diseases (Hori et al., 2011). In this study, a positive correlation between the ANP concentration and the left atrial-to-aortic root diameter could be demonstrated, which confirms that natriuretic peptides are released in cases of atrial stretch (Shionoria-ANP, Shionogi Co, Osaka, Japan). A similar correlation has been found in cats with cardiomyopathy (Hori et al., 2008).

The (possible) use of natriuretic peptides in equine veterinary medicine

As stated above, no specific equine BNP or NT-proBNP test is yet available and no equine specific half-life has been determined. Therefore, equine biomarker studies are limited to the measurement of atrial natriuretic peptides with human assays. Gehlen et al. (2007) and Trachsel et al. (2011) have already determined normal values for horses (15.6–26.4 pg/mL and 7.2–34 pg/mL) using two different human radioimmunoassays (RIA S2011 Peninsula Laboratories, San Carlos, USA; RIA RK-005-06 ANP-α, Phoenix Pharmaceutica Inc.), and found a positive correlation between the ANP concentration and left atrial enlargement.

In contrast to human and small animal veterinary medicine, the extra-cardiac influences on natriuretic peptides have been poorly investigated in horses. An important effect of exercise has been described (Kokkonen, 2002). In this study, the maximum ANP and NT-proANP values were reached respectively 5 and 30 minutes after exercise, and both peptides remained high until 60 minutes post-exercise. In anticipation of further studies, samples should therefore not be taken after exercise. Sample handling and stability of the molecules should also be taken into account. Stability studies conducted in human medicine have not revealed any clear standard sampling technique (Nelesen et al., 1992; Buckley et al., 1999; Zolty et al., 2008). Since no stability studies have been established for equine ANP and NT-proANP, human data are often extrapolated (Gehlen et al., 2007; Trachsel et al., 2011). However, this should always be done with caution, since species differences do exist. Therefore, details of sample handling and storage are imperative for the correct interpretation of the results. Reliable results can be obtained if aprotinin (a proteinase-inhibitor) is added to blood EDTA (ethylenediaminetetraacetic acid) samples and centrifuged at 4°C within 30 minutes. Plasma storage at -80°C is preferred until the assay is performed. Since significant ANP degradation has been shown in samples stored at -80°C for seven days, plasma samples should be assayed immediately or within a few days (Nelesen et al., 1992).

THE TROPONINS, MARKERS OF MYOCYTE INJURY

Physiology and structure

Troponins are part of the contractile apparatus of muscle tissue and can be found both in skeletal and cardiac muscles. They form a complex consisting of three interacting proteins: troponin I, T and C (Sandersen et al., 2008). Expression of cardiac isoforms with unique contractile properties is found in the heart, and is normally not present in adult skeletal muscle (Parmacek and Solaro, 2004). However, cardiac troponin T expression has been described in regenerating skeletal muscles in patients with skeletal myopathies (Maynard
et al., 2000). Troponins are mainly bound to myofibrils and only 6-8 % of cardiac troponin T (cTnT) and 2.8-4.1 % of cardiac troponin I (cTnI) can be found in the cytosol. Damaging cardiac myocytes primarily causes release of the cytosolic troponin pool. At a slower rate, the structurally bound troponins are released, which sustains the troponin elevation (Maynard et al., 2000). The concentrations begin to rise 4-8 hours after ischemic injury until a peak is found after 12-24 hours. The levels of cTnT and cTnI remain raised for 10-14 days and 7-10 days, respectively.

The use of cardiac troponins in human and small animal veterinary medicine

The primary role of cardiac troponin testing in humans is the diagnosis of acute myocardial infarction (AMI). In the last decade, troponins have replaced the less sensitive lactate dehydrogenase (LDH) and creatine kinase-myocardial band (CK-MB) isoenzymes. Not only are troponins more specific, their elevations remain longer, making them (besides NT-proBNP) an excellent biomarker for the detection of AMI (Maynard et al., 2000; Wells and Sleeper, 2008). Currently, cTnT is mostly used in human clinical practice. However, cTnI is comparable in diagnostic and prognostic efficacy. Some authors even claim cTnI superiority in cases of renal impairment and skeletal muscle damage, since cTnT specificity for cardiac muscle may not be absolute (Maynard et al., 2000). The use of the newer fourth generation cTnT assays could possibly limit cross reactivity in patients with renal disease. However, primary skeletal muscle disease could still cause false positive results (Jaffé et al., 2011).

In contrast to natriuretic peptides, the cardiac troponin structure is very conserved across species, which indicates that human assays can be utilized in different animals (O’Brien et al., 1998). In dogs, reference values for cTnI have already been established using a human immunoassay (Acces Accu TnI Assay Beckman Coulter, Inc., Fullerton, CA) and a human point-of-care cTnI analyzer (i-STAT 1 handheld clinical analyzer, Heska Corporation, Loveland, CO) (Oyama and Sisson, 2004; Payne et al., 2011). An increase in cTnI has been reported in dogs with cardiomyopathy, subvalvular aortic stenosis, mitral valve disease and cardiac causes of respiratory distress (Oyama and Sisson, 2004; Linklater et al., 2007; Bakirel and Gunes, 2009). Similar studies in cats have described the rise of cTnI in cats with cardiac dyspnea (Herndon et al., 2008). In comparison with cTnI, cardiac troponin T seems less sensitive for the diagnosis of cardiac diseases in dogs. The exact reason is still unknown, but Linklater et al. (2007) suggested that the smaller size of cTnI (molecular weight: 22 000 Da) could lead to an easier release of this molecule from the tropomyosin complex than the bigger cTnT protein (molecular weight: 40 000 Da). This size difference could also explain the higher values of cTnT in patients with renal failure, since the renal clearance of the large cTnT is more compromised (Payne et al., 2011).

The use of troponins in equine veterinary medicine

Currently, cardiac troponin I is the only cardiac biomarker which has been successfully used in equine veterinary practice for the evaluation of myocardial damage. Reference values have been established with different assays, and recently, the equine cTnI half-time has been determined.

A mean serum cTnI concentration of 0.047 ± 0.085 ng/mL has been reported in Thoroughbred horses with the Dimension Heterogeneous Immunoassay Module (Siemens, Newark, DE) (Phillips et al., 2003). The same breed was studied by Begg et al. (2006), in which serum and plasma cTnI concentrations under the detection limit (<0.15 ng/mL) were found in all healthy horses using a commercial assay (ADVIA Centaur cTnI assay, Bayer Corporation, Pittsburg, PA, USA). In a more recent study, a point-of-care analyzer (i-STAT 1, Heska Corp, Loveland, Colorado) was compared with a Beckman Access Immunoassay (Ohio State University Medical Center Reference Laboratory, Columbus, Ohio), achieving plasma concentrations from 0.0-0.06 ng/mL for normal healthy horses of different breeds (Kraus et al., 2010).

One should keep in mind that reference values can vary among different assays and laboratories. Thus, a sample from a horse with cardiac problems should always be compared with assay-specific reference values. As the half-life is 0.47h in horses, a persistent high cTnI value correlates with ongoing myocardial damage (Kraus et al., 2011). This short half-life also influences the optimal time for determining maximal elevations of cTnI. In theory, the optimal sampling time is 1-2h after a suspected maximal increase of cTnI. Similar to ANP, exercise results in an increase of cTnI (Nostell and Hägström, 2008). Not only the time of sampling but also sample handling can affect results. Since sample stability depends on the assay antibody configuration, sample type and handling should be performed according to the manufacturer’s instructions (Tate and Panthegini, 2008). Abbot Laboratories for example recommends centrifugation of serum samples (after complete clot formation) at 2500-3000 g for 10 minutes if testing is delayed for more than eight hours. According to these instructions, samples can be stored up to 72 hours at 2-8 °C and up to 30 days when frozen at a maximum temperature of -10 °C (Manual of the Architect STAT troponin I system, Abbott Laboratories, Abbott Park, Illinois).

If all these factors are taken into consideration, cTnI concentration can be used in daily equine practice for the detection of myocardial damage. In the literature, the use of cTnI has been increasingly described in horses, and retrospective studies show positive associations between an increase in cTnI and the degree of cardiac damage at necropsy (Divers et al., 2009; Kraus et al., 2010). In some case reports, this increase is extremely high. In a study by Schwarzwald et al. (2003), a cTnI concentration of 404 ng/mL was measured (ADVIA Centaur cTnI assay, Bayer Corporation, Pitts-
burgh PA) in a horse with multiform ventricular tachycardia. An even higher value (816 ng/mL) has been reported in a horse with lasalocid intoxication (De-cloedt et al., 2012).

In contrast to human medicine, the cardiac troponin T molecule has a lower diagnostic value in horses. In one study, a human quantitative (Enzym Linked Immunosor bent Assay from Boehringer Mannheim) and qualitative assay (Trop T Sensitive Rapid Assay, Roche Diagnostics, Mannheim, Germany) were used (Gehlen et al., 2006). Similar to cTnI, all of the healthy horses had normal values under the limit of detection (<0.06 ng/mL). A significantly higher cTnT value was found in horses with severe valve insufficiencies and cardiac dilatation. No significant increase could be demonstrated in horses with moderate valve insufficiencies without cardiac dilatation. Another important result was the surprisingly high cTnT value in 11 horses with atypical myopathy (Gehlen et al., 2006). Since atypical myopathy causes extreme muscle damage, a cross reaction between myocardial and skeletal cTnT could explain these high values. However, cardiac damage with elevation of cTnI has also been described in patients with atypical myopathy (Verheyen et al., 2012). A high cTnT value was also found in a horse with renal failure. Although it concerned only one horse, the case highlights the importance of renal clearance when interpreting cTnT elevations. Cardiac troponin T has also been measured in horses with atrial fibrillation before and after transvenous electrical cardioversion (Megurin et al., 2008). Since all concentrations were below the limit of detection, no increase could be observed.

ALDOSTERONE

Physiology and structure

The normal physiology of the renin-angiotensin-aldosterone system (RAAS) is shown in Figure 2. Its main function is the monitoring of blood flow, pressure, oxygen and Na⁺ concentrations (Muñoz et al., 2010). In response to a decrease in one of these parameters, renin is released from the juxtaglomular apparatus in the kidney, which transforms the circulating angiotensinogen into the biologically inert angiotensin I. Subsequently, angiotensin I is cleaved by the angiotensin converting enzyme (ACE) into the biologically active angiotensin II. This has various effects, including aldosterone secretion, which increases blood flow and blood pressure by stimulating Na⁺ reabsorption and vasoconstriction (Weber, 2001).

Aldosterone release in horses with cardiac problems

In case of cardiac failure, the decreased arterial filling activates the RAAS, which raises the aldosterone concentration. In response to this aldosterone release, water retention increases for the maintenance of the blood flow. Unfortunately, this volume expansion exacerbates diastolic wall stress and increases afterload, which further deteriorates the already reduced ventricular function (Muñoz et al., 2010).

The correlation between aldosterone concentration and cardiac disease has already been observed in humans and dogs (Böhm et al., 2011; Haggstrom et al., 1997). Unfortunately, aldosterone failed as guidance molecule for the treatment of heart failure. Only one study has been performed in horses with cardiac disease, in which a significant difference in aldosterone concentration between healthy horses and horses with left atrial and left ventricular enlargement was found (Gehlen et al., 2008). However, no specific cut-off value for severity of heart valve diseases was derived, emphasizing the need for further research.

Besides cardiac disease, many non-cardiac factors, such as sodium intake, exercise and circadian rhythm, influence aldosterone concentration (Guthrie et al., 1982; Harris, 1993). In humans, a diurnal aldosterone rhythm has been determined with maximal and minimal values round 08:00h am and 02:00h am, respectively (Chiang et al., 1994). Such a diurnal variation was...
also noted in a study in horses by Jansson et Dahlborn, 1999. However, the highest values were reported during the evening and in the night. Human and equine aldosterone are identical, thus a human radio-immunoassay can be used to measure aldosterone concentrations in horses (Harris, 1993). Besides sampling time, sample handling and storage should also be taken into account in clinical practice. Aldosterone plasma and serum samples were stable for 120h at 4°C in one study (Evans et al., 2001). However, individual laboratory recommendations should always be followed.

CONCLUSION

Cardiac biomarkers are intensively used in human and small animal veterinary medicine for the diagnosis and prognosis of heart diseases. This trend will further develop in equine medicine and stimulates equine specific studies and the development of assays. Currently, only cardiac troponin I can be used in equine clinical practice for the diagnosis of myocardial damage, thereby replacing the less specific LDH and CK-MB iso-enzymes. In the future, natriuretic peptides will become more important to estimate the diagnosis and prognosis of heart diseases in horses.

LITERATURE


